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Abstract
Purpose: The purpose of this study is to clarify the prognostic significance of expression of Jab1, p16, p21, p62, Ki67 and
Skp2 in soft tissue sarcomas (STS). Optimised treatment of STS requires better identification of high risk patients who will
benefit from adjuvant therapy. The prognostic significance of Jab1, p16, p21, p62, Ki67 and Skp2 in STS has not been
sufficiently investigated.
Experimental Design: Tissue microarrays from 193 STS patients were constructed from duplicate cores of viable and
representative neoplastic tumor areas. Immunohistochemistry was used to evaluate the expression of Jab1, p16, p21, p62,
Ki67 and Skp2.
Results: In univariate analyses, high tumor expression of Ki67 (P = 0.007) and Skp2 (P = 0.050) correlated with shorter
disease-specific survival (DSS). In subgroup analysis, a correlation between Skp2 and DSS was seen in patients with
malignancy grade 1 or 2 (P = 0.027), tumor size .5 cm (P = 0.018), no radiotherapy given (P = 0.029) and no chemotherapy
given (P = 0.017). No such relationship was apparent for Jab1, p16, p21 and p62; but p62 showed a positive correlation to
malignancy grade (P = 0.019). Ki67 was strongly positively correlated to malignancy grade (P = 0.001). In multivariate
analyses, Skp2 was an independent negative prognostic factor for DSS in women (P = 0.009) and in patients without
administered chemotherapy or radiotherapy (P = 0.026).
Conclusions: Increased expression of Skp2 in patients with soft tissue sarcomas is an independent negative prognostic
factor for disease-specific survival in women and in patients not administered chemotherapy or radiotherapy. Besides,
further studies are warranted to explore if adjuvant chemotherapy or radiotherapy improve the poor prognosis of STS with
high Skp2 expression.
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Introduction
Soft tissue sarcomas (STS) are a heterogeneous and highly
malignant group of tumors originating from mesenchymal lineage.
Local recurrence is common (20%) and metastases occur in one
third of patients [1]. Prognostic markers in potentially curable STS
should guide therapy after surgical resection. Neoadjuvant therapy
is increasingly used and may improve prognosis in high-risk cases
[2], but requires prognostic factors that can be evaluated
preoperatively. Currently used prognostic factors mainly include
clinicopathological variables such as tumor type, size, depth,
malignancy grade, necrosis, vascular invasion, and growth pattern,
which are combined into different prognostic systems [3–9].
The loss of cell cycle control is a critical step in the development
of neoplasia. The cell cycle is a series of carefully coordinated and
regulated steps that govern cellular proliferation. Cyclin-depen-
dent kinases (CDK) phosphorylate the retinoblastoma (Rb)
protein, a classic tumor suppressor and key component of the
G1/S checkpoint. This allows DNA replication to proceed.
Inhibitors of CDK, such as p16INK4A, p21, and p27 act as brakes
on progression through the cell cycle.
The human Jun activation domain binding protein 1 (Jab1) was
originally identified as a coactivator of the gene regulatory AP-1
proteins (Jun/Fos protooncogenes) involved in the control of cell
proliferation [10]. Jab1 directly binds to p27 and induces nuclear
export and subsequent degradation [11]. Some studies indicated
that Jab1 can interact specifically with the protein form of the
CDK inhibitor 27 and shuttle p27 from the nucleus to the
cytoplasm. And further to decrease the cellular amount of p27 by
accelerating p27 degradation via the ubiquitin-proteasome system
[12,13]. Other reports have shown that overexpression of Jab1
and low expression of p27 is associated with more advanced tumor
stage and poor prognosis in several human cancers [11,14–16].
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The CDK inhibitor p16INK4a (p16) protein belongs to the INK4
family of CDK inhibitors [17]. CDK inhibitors are negative
regulators of the process of pRb hyperphosphorylation. The INK4
family of CDK inhibitors binds to CDK4/6 and the D family of
cyclins to prevent formation of the cyclin–CDK complex required
to phosphorylate pRb [17]. p16 has been identified as a tumor
suppressor [18]. The gene encoding p16 is deleted in a high
percentage of malignant cell lines and tissues [19–21]. p16 is
important in cell senescence, and some studies have identified a
role for p16 in cell proliferation and angiogenesis [22,23]. A model
of murine rhabdomyosarcoma has been produced through a
subsequent genetic manipulations, among others p16 deletion
[24,25]. Still, the role of cell cycle regulators in the genesis of
mesenchymal neoplasia is less well studied and the role of the p16
protein in STS has not been sufficiently investigated.
p21 (Waf1) is a cell cycle regulator, implicated in a variety of
pathways [26]. The product of the CDKN1A gene (p21) binds to
and inhibits the activity of CDK2/4 complexes, and thus functions
as a regulator of cell cycle progression at the G1 checkpoint. Ki67
is involved in the synthesis of ribosomes and appears to be a
necessary requirement for cell proliferation [27].
The intricate signalling network that determines whether cells
grow, undergo senesce or die, achieves a remarkable degree of
specificity with a relatively small number of signalling molecules
[28]. Studies employing knockout, transgenic, and knockin mice
have shown that p62 plays critical roles in a number of cellular
functions, including bone remodelling, obesity, and cancer [29–
31].
S-phase kinase-associated protein 2 (Skp2) is a member of
mammalian F-box proteins, which displays S-phase-promoting
function through ubiquitin-mediated proteolysis of the CDK
inhibitor p27. Skp2 has been shown to regulate cellular
proliferation by targeting several cell cycle-regulated proteins for
ubiquitination and degradation. Skp2 has also been demonstrated
to display an oncogenic function since its overexpression has been
observed in many human cancers [32].
The purpose of this study was to clarify the prognostic
significance of Jab1, p16, p21, p62, Ki67 and Skp2 expression
in non-gastrointestinal stromal tumor (non-GIST) STS. To
achieve this, we analyzed the expression of these markers in 193
patients with non-GIST STS in relation to demographic and other
clinicopathological variables.
Materials and Methods
Patients and Clinical Samples
The National Cancer Data Inspection Board and The Regional
Committee for Research Ethics (REK nord) approved the study.
The material was collected from our approved biobank for
paraffin embedded material and slides. The Regional Committee
Figure 1. Immunohistochemistry microscopic pictures of tissue micro array of soft tissue sarcoma representing different
expression of p62 and Skp2. (A) p62 low score; (B) p62 high score; (C) Skp2 low score; (D) Skp2 high score. Original magnification 6 400.
doi:10.1371/journal.pone.0047068.g001
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Table 1. Prognostic clinicopathological variables as predictors for disease-specific survival of soft tissue sarcomas (univariate











#20 years 17 9 190 47 0.064
21–60 years 85 44 235 63
.60 years 91 47 111 51
Gender
Male 81 42 235 60 0.087
Female 112 58 180 53
Nationality
Norwegian 131 68 228 62 0.005
Russian 62 32 81 44
Histology
Pleomorphic sarcoma 57 30 52 45 0.031
Leiomyosarcoma 47 24 89 64
Liposarcoma 32 17 NR 71
MF/MFT 16 8 123 56
Angiosarcoma 8 4 10 38
Rhabdomyosarcoma 9 5 NR 67
MPNST 9 5 NR 56
Synovial sarcoma 12 6 31 30
Other STS 3 2 NR –
Tumor localization
Extremities 78 40 201 56 0.922
Trunk 37 19 214 53
Retroperitoneum 27 14 135 51
Head/Neck 13 7 191 58
Visceral 38 20 202 62
Tumor size
,5 cm 57 30 257 69 0.026
5–10 cm 73 38 183 54




1 61 28 316 81 ,0.001
2 98 39 173 55
3 90 33 103 36
Surgical margins
Wide 97 50 254 66 ,0.001
Non-wide 96 50 128 46
Chemotherapy
No 156 81 207 57 0.669
Yes 37 19 180 51
Radiotherapy
No 132 68 216 58 0.190
Yes 61 32 152 52
Abbreviations: MF/MFT, malignant fibroblastic/myofibroblastic tumors; MPNST, malignant peripheral nerve sheath tumor; STS, soft tissue sarcomas; NR, not reached;
NOS, non specified.
doi:10.1371/journal.pone.0047068.t001
Impact of Jab1, p16, p21, p62, Ki67, Skp2 in STS
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approved that written consent from the patients for their
information to be stored in the hospital database and used for
research was not needed because most of the material was more
than 10 years old, and most of the patients being dead. The ethics
committee specifically waived the need for consent. Data were
analyzed anonymously.
Primary tumor tissues from patients diagnosed with STS at the
University Hospital of North Norway (UNN) from 1973 to 2006
and the Hospitals of Arkhangelsk region, Russia, were used in this
retrospective study. In total, 496 potentially suitable patient
records were identified from the hospitals databases. Of these,
247 patients were excluded due to missing clinical data (n = 86) or
inadequate material for histological examination (n = 161). In
addition 33 were excluded because of metastasis at the time of the
diagnosis, 13 were excluded because they had no surgery, and 10
patients had both metastasis and no surgery. Eligible for this study
were 193 patients. This report includes data for 131 Norwegian
patients and 62 Russian patients followed until September 2009.
The median follow-up was 38 (range 0–392) months. Complete
demographic and clinical data were collected retrospectively.
Formalin-fixed and paraffin-embedded tumor specimens were
obtained from the archives of the Departments of Pathology at
UNN and Archangelsk. The tumors were graded according to the
French Fèdèration Nationales des Centres de Lutte Contre le
Cancer (FNCLCC), [WHO Tumors of Soft Tissue and bone,
2002]. Wide resection margins were defined as wide local resection
with free microscopic margins or amputation of the affected limb
or organ. Non-wide resection margins were defined as either
marginal or intralesional resection margins.
Tissue Microarray Construction
The histology of all soft tissue sarcoma cases were reviewed by
two pathologists (AV and SWS). Tissue microarrays (TMAs) were
constructed for high-throughput molecular pathology research
[33]. The most representative areas of viable tumor cells were
carefully selected and marked on the hematoxylin and eosin (HE)
slides for the corresponding donor blocks and sampled for the
tissue microarray collector blocks. The TMAs were assembled
using a tissue-arraying instrument (Beecher Instruments).
Studies suggest that punching multiple 0.6 mm cores from
different regions captures the heterogeneity of the tumors more
accurately than single 2 to 4 mm core [34]. Hence, we chose using
two 0.6-mm cores of viable neoplastic tissue that were selected to
be as representative as possible (different areas), after reviewing all
original sections of the tumor and taking the heterogeneity in
consideration. To include all core samples, 12 tissue array blocks
were constructed. Multiple 4-mm sections were cut with a Micron
microtome (HM355S) and stained by specific antibodies for
immunohistochemistry (IHC).
Immunohistochemistry (IHC)
All staining were performed in the Ventana Benchmark XT
automated slide stainer (Ventana Medical System, Illkirch,
France). Before staining the sections were incubated at 60 degrees
Celsius over night. Tissue sections were incubated with primary
mouse monoclonal antibodies recognizing Jab1 (Zymed, catalog
number 18–7386, 1:50), Skp2 (Zymed, catalog number 18–0307,
1:10), p62 (BD Biosciences, catalog number 610832, 1:50), Ki67
(Ventana, catalog number 790–4286, ready to use) and p21 (Dako,
catalog number M7202, 1:25), p16 (MTM lab, Germany, catalog
number 9511, ready to use). We used a Ventana antibody diluent
(catalog number 251-018). The incubation periods were 28
minutes for Jab1, 28 minutes for p16, 32 minutes for p62 and
Ki67, 40 minutes for p21 and Skp2. This was followed by
application of liquid diaminobenzidine as substrate-chromogen,
yielding a brown reaction product at the site of the target antigen
(Ventana iView DAB Detection Kit, catalog number 760–091).
iVIEW DAB Detection Kit is an indirect biotin streptavidin
system for detecting mouse and rabbit primary antibodies. The
DAB chromogen produces a dark brown precipitate that is readily
visualized by light microscopy. All reagents are provided pre-
diluted by the manufacturer for use in Ventana Benchmark XT.
Finally, slides were counterstained with hematoxylin to visualize
the nuclei. For each antibody, including negative controls, all
TMA staining were performed in a single experiment. In the TMA
we also used cores from carcinomas and normal tissue as positive
and negative controls.
Scoring of IHC
The ARIOL imaging system (Genetix, San Jose, CA) was used
to scan the slides for antibody staining of the TMAs. The
specimens were scanned at a low resolution (1.256) and high
resolution (206) using an Olympus BX 61 microscope with an
automated platform (Prior). The slides were loaded in the
automated slide loader (Applied Imaging SL 50). In our
experience it was difficult for the ARIOL imaging system to
distinguish between tumor and stroma in soft tissue sarcomas.
Representative and viable tissue sections were therefore scored
manually on a computer screen semi-quantitatively for nuclear
and/or cytoplasmic staining, Figure 1. The expression of Jab1,
p16, p21, p62, Ki67 and Skp2 was scored as: 0, negative; 1, weak;
2, intermediate; 3, strong. The score for each patient was based on
the mean scoring of cores from one or several biopsies. To achieve
maximal reproducibility in all cases, every staining was dichot-
omised (low and high expression). Instead of using the overall
mean score as cutoff, the cutoffs were chosen at levels securing
statistically sufficient numbers in each group and appearing most
biologically plausible. Hence, in this study the cutoff values varied
among the different markers. High expression was defined as
mean score .0 for p21 and Skp2, $0.33 for p62, $0.75 for p16
and $2.00 for Jab1 and Ki67. All samples were anonymized and
independently scored by two pathologists (AV and SWS). In case
of disagreement, the slides were re-examined and a consensus was
reached by the observers. When assessing a variable for a given
score, the scores of the other variables and the outcome were
hidden from the observers.
Statistical Methods
All statistical analyses were done using the statistical package
SPSS (Chicago, IL), version 18. The IHC scores from each
observer were compared for interobserver reliability by use of a
two-way random effect model with absolute agreement definition.
The intraclass correlation coefficient (reliability coefficient) was
obtained from these results.
The Chi-square test and Fishers Exact test were used to
examine the association between molecular marker expression and
various clinicopathological parameters. Univariate analyses were
done using the Kaplan-Meier method, and statistical significance
between survival curves was assessed by the log rank test. Disease-
specific survival (DSS) was determined from the date of
histological-confirmed STS diagnosis. Correlation of marker
expression was done using the Pearson correlation (2 tailed) at
the 0.05 and the 0.01 level.
Multivariate analysis was carried out using the Cox proportional
hazards model to assess the specific impact of each pre-treatment
variable on survival in the presence of other variables. Only
variables of significant value from the univariate analysis were
entered into the Cox regression analysis. Probability for stepwise
Impact of Jab1, p16, p21, p62, Ki67, Skp2 in STS
PLOS ONE | www.plosone.org 4 October 2012 | Volume 7 | Issue 10 | e47068
Impact of Jab1, p16, p21, p62, Ki67, Skp2 in STS
PLOS ONE | www.plosone.org 5 October 2012 | Volume 7 | Issue 10 | e47068
entry and removal was set at 0.05 and 0.10, respectively. The
significance level used was P,0.05.
Results
Clinicopathological Variables
Demographic, clinical, and histopathological variables are
shown in Table 1. Patient age ranged from 0–89 years (mean 55
years), and 42% of patients were male. The treatment option of
choice was surgery (N = 193): 104 patients received surgery only;
52 patients received surgery and radiotherapy; 28 patients
received surgery and chemotherapy; 9 patients received surgery,
radiotherapy and chemotherapy. The 5-year survival for patients
with wide and non-wide resection margins was 66% and 46%
respectively, Table 1.
Inter-observer Variability
There was good scoring reproducibility between the two
investigating pathologists. Their scoring agreement was tested for
p62 and Skp2. The IHC scores from each observer were
compared using a two-way random effect model with absolute
agreement definition. The intra-class correlation coefficients
(reliability coefficients, r) obtained from these results were 0.82
for p62 (P,0.001) and 0.94 for Skp2 (P,0.001).
Univariate Analyses
Nationality, histology, tumor size, malignancy grade and
surgical margins were all significant indicators for disease-specific
survival (DSS) in univariate analyses, Table 1.
In univariate analyses, increased expression of Ki67 (P = 0.007)
and Skp2 (P = 0.050) correlated significantly with a shorter DSS,
Table 2 and Figure 2. No such relationship was apparent for Jab1,
p16, p21 and p62, but expression of p62 was positively correlated
to malignancy grade (P = 0.019), Table 3. Ki67 was strongly
positively correlated to malignancy grade (P = 0.001), Table 3.
High expression of the different markers was significantly
correlated. There was weak (r = 0.20–0.29), moderate (r = 0.30–
0.39) and strong (r = 0.40–0.69) positive correlations between the
various examined markers. There was strong correlation between
p16 and p62, strong correlation between Ki67 and p21/Skp2,
Figure 2. Disease-specific survival curves for high and low expression of different markers in patients with soft tissue sarcomas
(N = 193).
doi:10.1371/journal.pone.0047068.g002
Table 2. Expression of markers and their prediction for disease-specific survival in patients with soft tissue sarcomas (univariate











Low 95 49 76 54 0.701
High 83 43 123 59
Missing 15 8
p16
Low 84 13 80 51 0.562
High 100 52 123 62
Missing 9 5
p21
Low 75 39 NR 59 0.426
High 109 56 89 56
Missing 9 5
p62
Low 58 30 NR 59 0.255
High 129 67 76 55
Missing 6 3
Ki67
Low 28 15 NR 68 0.007
Medium 56 29 NR 66
High 99 51 57 48
Missing 10 5
Skp2
Low 109 56 NR 63 0.050
High 67 45 59 50
Missing 17 9
Abbreviations: NR, not reached.
doi:10.1371/journal.pone.0047068.t002
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moderate correlation between Jab1 and p21/p62/Skp2, moderate
correlation between p21 and p62/Skp2 and moderate correlation
between Ki67 and Jab1/p16/p62, Table 4.
In subgroup analyses (Table 5), increased Skp2 expression was
associated with a shorter DSS in Norwegian patients (P = 0.021),
those with malignancy grade 1 and 2 tumors (p = 0.027), tumors
larger than 5 cm (P = 0.018), without radiotherapy (P = 0.029) and
without chemotherapy (P = 0.017), Figure 3. There were no
significant differences in the expression of the different immuno-
markers in the different histological tumor groups (data not
shown).
Multivariate Analyses
Demographic, clinicopathological, and expression variables
from the univariate analyses were entered into the multivariate
Cox regression analysis (Table 6). In the multivariate analysis, age
(P = 0.012), malignancy grade (P,0.001) and wide resection
margins (P = 0.001) were independent prognostic factors for
DSS. In addition, Skp2 had an independent prognostic impact
in women (P = 0.009) and in patients not treated with chemother-
apy or radiation (P = 0.026).
Discussion
In this large scale study, we evaluated whether there is an
association between tumor cell expression of Jab1, p16, p21, p62,
Ki67 and Skp2 and survival in 193 non-GIST STS patients.
Increased expression of Skp2 in patients with STS was an
independent negative prognostic factor for DSS in women and in
patients not administered chemotherapy or radiotherapy. To our
knowledge, this is the first report where Skp2 is compared with
Jab1, p16, p21 and p62 in STS and the first evidence of its possible
clinical relevance in STS patients regarding potential benefits for
adjuvant treatment with chemotherapy or radiation in the
subgroup of patients with high expression of Skp2.
STS has different biological characteristics regardless of its
histological phenotype. Its prognosis is in general poor, but also
difficult to predict. In potentially curable STS prognostic markers
should, ideally, guide further therapy following surgical resection.
In our material, high expression of the different cell cycle control
markers were significantly correlated. This is, however, expected
since there is overlap in their mechanisms of action. Tsuchida et
al. [35] suggested that Jab1 may play an important role in
determining the differentiation stage of rhabdomyosarcoma cells
by modulating the activity of CDK inhibitor p27. However, in our
material, Jab1 showed no correlation with malignancy grade and
had no prognostic impact on DSS in STS.
Epigenetic silencing of p16 might be critical early initiating
events in the tumorigenesis of Ewing sarcoma family tumors [36].
p16 has been shown as a sensitive and specific marker for
distinguishing atypical lipomatous tumor-well-differentiated lipo-
sarcoma and dedifferentiated liposarcoma from benign adipocytic
neoplasms [37]. There is overexpression of p16 in uterine
leiomyosarcoma compared to benign leiomyoma and normal
myometrium [38]. p16 and pRb immunohistochemical expression
increases with increasing tumour grade in mammary phyllodes
tumours [39]. In a series of 38 pediatric osteosarcomas there was
an inverse correlation between loss of pRB and p16 expression.
Absence of p16 expression significantly correlated with decreased
survival in univariate analysis [40]. Immunohistochemically
decreased expressions of p16 was associated with poor prognosis
in malignant peripheral nerve sheath tumor [41]. In a series of 21
Table 3. Results of expression of p21, p62, Ki67 and Skp2 versus malignancy grade in patients with soft tissue sarcomas, N = 193.
Expression Malignancy grade (%)
Grade 1 Grade 2 Grade 3 Total Missing Chi-Square P-value
p21, Low 25 (33) 26 (35) 24 (32) 75 9 1.420 0.492
p21, High 28 (26) 45 (41) 36 (33) 109
Total 53 (29) 71 (39) 60 (33) 184
p62, Low 24 (41) 17 (29) 17 (29) 58 6 7.893 0.019
p62, High 28 (22) 55 (43) 46 (36) 129
Total 52 (25) 72 (38) 63 (38) 187
Ki67, Low 13 (46) 8 (29) 7 (25) 28 10 18.525 0.001
Ki67, Medium 22 (39) 22 (39) 12 (21) 56
Ki67, High 15 (15) 42 (42) 42 (42) 99
Total 50 (27) 72 (39) 61 (33) 183
Skp2, Low 36 (33) 41 (38) 32 (29) 109 17 1.797 0.407
Skp2, High 16 (24) 27 (40) 24 (36) 67
Total 52 (30) 68 (39) 56 (32) 176
doi:10.1371/journal.pone.0047068.t003
Table 4. Correlation of marker expression in patients with
soft tissue sarcomas (Pearson correlation), N = 193.
Marker
expression Jab1 p16 p21 P62 Skp2 Ki67
Jab1 – 0.243** 0.372** 0.315** 0.305** 0.398**
p16 0.243* – 0.208** 0.418** 0.275** 0.332**
p21 0.372** 0.208** – 0.360** 0.312** 0.418**
p62 0.315** 0.418** 0.360** – 0.195* 0.368**
Skp2 0.305** 0.275** 0.312** 0.195* – 0.456**
Ki67 0.398** 0.332** 0.418** 0.368** 0.456** –
*Correlation is significant at the 0.05 level (2 tailed).
**Correlation is significant at the 0.01 level (2 tailed).
doi:10.1371/journal.pone.0047068.t004
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uterine leiomyosarcomas, no statistically significant correlation
between p16 expression and clinical stage, age, vascular space
involvement, and recurrent disease could be found. Additionally,
the overall survival did not significantly differ between p16-positive
and p16-negative cases [42]. In a series of 84 uterine leiomyosar-
comas, p16 did not show any significant correlation with survival
[43]. Shim et al. [44] found no significant difference between the
survival rate according to the p16 expression in 66 soft tissue
sarcomas. In our material there was no correlation of p16 and
malignancy grade or DSS.
Using in vivo RNA interference, Young et al. implicated the p53
target gene p21 as a critical mediator in sarcomagenesis [45]. The
expression of p21 was closely associated with tumor malignancy
grade, and therefore considered used as prognostic markers in a
series of 152 STS [46]. López-Guerrero et al observed that the
expression of p21 (P,0.015) was higher in disseminated than
localized disease in patients with Ewing’s sarcoma tumors, but p21
did not influence progression free or overall survival [47]. In a
series of 36 patients with leiomyosarcoma, p21 was not correlated
with time to recurrence or overall survival [48]. Similarly, in our
material p21 was not correlated to malignancy grade or DSS. This
can be due to other bypass molecules involved in p53 suppression
functions.
There are few publications regarding p62 and STS. Rolland et
al. demonstrated that p62 expression in breast cancer is associated
with tumor progression, but not DSS [49]. In a series of 109 non-
small cell lung cancers, p62 were an independent factors
predicting worse lung cancer-specific survival [50]. Kitamura et
al. demonstrated cytosolic overexpression of p62 in prostate
adenocarcinoma and high-grade PIN, suggesting that p62 might
be a novel marker for prostatic malignancy [51]. However, in a
series of 59 colorectal carcinomas, p62 had no prognostic value
[52]. In our material, p62 correlated with malignancy grade, but
not DSS.
Figure 3. Disease-specific survival curves for high and low expression of Skp2 in males (N = 81), females (N = 112) and in patients
not treated with chemotherapy or radiation (N = 104).
doi:10.1371/journal.pone.0047068.g003
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Table 5. Results of subgroup analysis of patients with expression of Skp2, N = 193.
Subgroup Patients (n) Patients (%) Median survival (months) 5-Year survival (%) P
Age
0–60 years, Skp2 Low 52 53 NR 71 0.074
0–60 years, Skp2 High 38 38 67 56
Missing 9 9
.60 years, Skp2 Low 57 61 80 57 0.188
.60 years, Skp2 High 29 31 36 42
Missing 8 9
Gender
Male, Skp2 Low 50 62 NR 63 0.577
Male, Skp2 High 23 28 67 61
Missing 8 10
Female, Skp2 Low 59 53 NR 63 0.066
Female, Skp2 High 44 39 49 44
Missing 9 8
Nationality
Norwegian, Skp2 Low 67 51 NR 71 0.021
Norwegian, Skp2 High 57 44 89 54
Missing 7 5
Russian, Skp2 Low 42 68 91 51 0.177
Russian, Skp2 High 10 16 41 16
Missing 10 16
Malignancy grade
1 or 2, Skp2 Low 77 59 NR 74 0.027
1 or 2, Skp2 High 43 33 89 56
Missing 10 8
3, Skp2 Low 32 51 26 37 0.970
3, Skp2 High 24 38 31 39
Missing 7 11
Tumor size
,5 cm, Skp2 Low 37 63 NR 64 0.610
,5 cm, Skp2 High 17 29 NR 75
Missing 5 8
.5 cm, Skp2 Low 71 53 NR 63 0.018
.5 cm, Skp2 High 50 37 49 41
Missing 13 10
Radiotherapy
No, Skp2 Low 77 58 NR 68 0.029
No, Skp2 High 45 34 58 46
Missing 10 8
Yes, Skp2 Low 32 52 62 53 0.744
Yes, Skp2 High 22 36 100 58
Missing 7 11
Chemotherapy
No, Skp2 Low 94 60 NR 66 0.017
No, Skp2 High 49 31 58 45
Missing 13 8
Yes, Skp2 Low 15 41 45 47 0.743
Yes, Skp2 High 18 49 89 61
Missing 4 11
Abbreviations: NR, not reached.
doi:10.1371/journal.pone.0047068.t005
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High expression of Skp2 was reported to correlate with reduced
overall survival in patients with myxofibrosacroma [53,54]. Di
Vizio et al. [55] found that Skp2 expression correlated with poor
prognosis in gastrointestinal stromal tumors (GIST). Oliveira
found that Skp2 expression is associated with cell proliferation and
a worse prognosis in 182 soft tissue sarcomas [56]. In our material,
high expression of Skp2 was a negative prognostic factor for DSS.
Interestingly, this correlation was statistically significant in women
only (P = 0.009), not men (P = 0.577). This may be related to
differences in expression of sexual hormone receptors (ER and
PGR) in male and female STS patients [57,58]. An inverse
correlation between Skp2 expression and the expression of ER and
PGR has been reported by others investigating breast cancer [59]
and other studies suggest that Skp2B may modulate the activity of
the estrogen receptor [60,61]. It should be a priority in further
studies to explore the relations of Skp2, gender and DSS.
Since the regulation of p27Kip1 degradation is mediated by its
specific ubiquitin ligase subunits S-phase kinase protein (Skp)2 and
cyclin-dependent kinase subunit (Cks)1, many have an inverse
correlation regarding overexpression of Skp2 and decreased
expression of p27Kip1, an analysis of p27Kip1 and other Skp2
target proteins such as p53 and Rb would be helpful for
substantiating the Skp2 observations. It has already been shown
that Skp2 deficiency can enhance sensitivity of leukemia cells to
chemotherapy [62] and Skp2 is itself being increasingly considered
a possible target for breast cancer and prostate cancer therapy
[63,64]. Wang et al. found a significantly negative correlation
between Skp2 expression and the survival of patients administered
radiotherapy, indicating that overexpression of Skp2 was corre-
lated with an increased radioresistance of esophageal squamous
cell carcinoma. This is in contrast to our findings where
chemotherapy and radiotherapy appear to reduce the negative
survival impact in patients with Skp2 expressing STS tumors.
In conclusion, our data suggest that an increased Skp2
expression in women with STS was an independent indicator of
a poor survival. Skp2 expression data may provide additional
information to guide adjuvant therapy after surgical resection.
Future studies are warranted to evaluate whether adjuvant
chemotherapy or radiotherapy will improve the poor prognosis
of Skp2 expressing soft tissue sarcoma patients.
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Table 6. Results of Cox regression analysis summarizing prognostic factors in patients with soft tissue sarcomas.
All patients, N = 193 No chemotherapy, no radiation, N = 104 Women, N = 112
Factor
Hazard
Ratio 95% CI P
Hazard
Ratio 95% CI P
Hazard
Ratio 95% CI P
Age
0–60 years 1.00 1.00 1.00
.60 years 1.79 1.14–2.81 0.012 3.64 1.64–8.09 0.001 1.60 0.89–2.90 0.118
Nationality
Norwegian 1.00 1.00 1.00
Russian 1.49 0.89–2.48 0.129 1.67 0.72–3.86 0.232 2.33 1.17–4.66 0.016
Tumor size
,5 cm 1.00 0.260* 1.00 0.963* 1.00 0.017*
5–10 cm 1.34 0.75–2.38 0.325 0.89 0.40–1.98 0.783 1.69 0.80–3.60 0.166
.10 cm 1.65 0.91–3.02 0.101 0.97 0.43–2.20 0.936 3.15 1.41–7.03 0.005
Malignancy grade FNCLCC
1 1.00 ,0.001* 1.00 0.004* 1.00 0.002*
2 2.70 1.37–5.32 0.004 2.36 1.04–5.34 0.040 4.79 1.93–11.88 0.001
3 4.86 2.45–9.65 ,0.001 4.66 1.87–11.61 0.001 4.86 1.91–12.34 0.001
Resection margins
Wide 1.00 1.00 1.00
Non-wide 2.19 1.38–3.48 0.001 3.32 1.65–6.69 0.001 1.03 0.56–1.92 0.923
Ki67
Low 1.00 0.392* 1.00 0.272* 1.00 0.214*
Medium 0.98 0.42–2.27 0.961 0.97 0.25–3.74 0.965 0.48 0.17–1.32 0.154
High 1.44 0.62–3.36 0.393 1.88 0.50–7.01 0.349 0.85 0.30–2.36 0.750
Skp2
Low 1.00 1.00 1.00
High 1.35 0–8622.11 0.194 2.05 1.09–3.86 0.026 2.32 1.23–4.36 0.009
*Overall significance as a prognostic factor.
doi:10.1371/journal.pone.0047068.t006
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